Skip to Content
Merck
  • Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.

Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.

Journal of clinical pharmacy and therapeutics (2010-11-09)
S-H Hsiao, H-H Chen, C-H Chou, W-L Lin, P-Y Liu Yeh, T-J Wu
ABSTRACT

Hypersensitivity syndrome associated with teicoplanin has rarely been reported. We report a case with a preceding episode of vancomyin-related neutropenia. A 47-year-old female with cervical spine infection was treated with vancomycin. Neutropenia occurred after 17 days of vancomycin therapy. Vancomycin was changed to teicoplanin, and the neutropenia resolved 4 days later. After 11 days of teicoplanin therapy, a new episode of hypersensitivity syndrome manifested as fever, bilateral neck lymphadenopathy, mild wheezing, hepatitis and increased CRP occurred. Neutropenia and thrombocytopenia developed 3 days later. The patient's symptoms settled over 1 week following withdrawal of teicoplanin. Naranjo's ADR algorithm categorized the neutropenia associated with vancomycin and the hypersensitivity syndrome associated with teicoplanin as 'probable'.

MATERIALS
Product Number
Brand
Product Description

Teicoplanin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Teicoplanin
Teicoplanin for identification, European Pharmacopoeia (EP) Reference Standard